132.39 USD
-0.96 (-0.72%)
132.39 USD
0 (0%)
Taking everything into account, NBIX scores 7 out of 10 in our fundamental rating. NBIX was compared to 525 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making NBIX a very profitable company, without any liquidiy or solvency issues. NBIX is growing strongly while it also seems undervalued. This is an interesting combination With these ratings, NBIX could be worth investigating further for value and growth and quality investing!.
1. Profitability
1.1 Basic Checks
- NBIX had positive earnings in the past year.
- NBIX had a positive operating cash flow in the past year.
- In the past 5 years NBIX has always been profitable.
- In the past 5 years NBIX always reported a positive cash flow from operatings.
1.2 Ratios
- NBIX has a Return On Assets of 10.03%. This is amongst the best in the industry. NBIX outperforms 93.90% of its industry peers.
- With an excellent Return On Equity value of 14.25%, NBIX belongs to the best of the industry, outperforming 94.48% of the companies in the same industry.
- Looking at the Return On Invested Capital, with a value of 11.10%, NBIX belongs to the top of the industry, outperforming 95.05% of the companies in the same industry.
- The Average Return On Invested Capital over the past 3 years for NBIX is significantly below the industry average of 18.07%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 10.03% | ||
| ROE | 14.25% | ||
| ROIC | 11.1% |
ROA(3y)7.79%
ROA(5y)10.24%
ROE(3y)11.14%
ROE(5y)15.22%
ROIC(3y)11.4%
ROIC(5y)11.57%
1.3 Margins
- NBIX has a Profit Margin of 15.95%. This is amongst the best in the industry. NBIX outperforms 92.38% of its industry peers.
- NBIX's Profit Margin has improved in the last couple of years.
- NBIX has a better Operating Margin (20.64%) than 95.05% of its industry peers.
- In the last couple of years the Operating Margin of NBIX has declined.
- The Gross Margin of NBIX (98.37%) is better than 97.71% of its industry peers.
- NBIX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.64% | ||
| PM (TTM) | 15.95% | ||
| GM | 98.37% |
OM growth 3Y10.53%
OM growth 5Y-2.95%
PM growth 3Y22.39%
PM growth 5Y25.28%
GM growth 3Y-0.06%
GM growth 5Y-0.1%
2. Health
2.1 Basic Checks
- NBIX has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
- The number of shares outstanding for NBIX has been increased compared to 1 year ago.
- Compared to 5 years ago, NBIX has more shares outstanding
- There is no outstanding debt for NBIX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- NBIX has an Altman-Z score of 7.86. This indicates that NBIX is financially healthy and has little risk of bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 7.86, NBIX is in the better half of the industry, outperforming 78.86% of the companies in the same industry.
- There is no outstanding debt for NBIX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 7.86 |
ROIC/WACC1.26
WACC8.83%
2.3 Liquidity
- A Current Ratio of 3.38 indicates that NBIX has no problem at all paying its short term obligations.
- NBIX's Current ratio of 3.38 is in line compared to the rest of the industry. NBIX outperforms 40.57% of its industry peers.
- A Quick Ratio of 3.27 indicates that NBIX has no problem at all paying its short term obligations.
- With a Quick ratio value of 3.27, NBIX perfoms like the industry average, outperforming 41.71% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.38 | ||
| Quick Ratio | 3.27 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an nice 12.06% over the past year.
- Measured over the past years, NBIX shows a very strong growth in Earnings Per Share. The EPS has been growing by 58.39% on average per year.
- Looking at the last year, NBIX shows a quite strong growth in Revenue. The Revenue has grown by 19.61% in the last year.
- Measured over the past years, NBIX shows a very strong growth in Revenue. The Revenue has been growing by 24.48% on average per year.
EPS 1Y (TTM)12.06%
EPS 3Y35.58%
EPS 5Y58.39%
EPS Q2Q%64.52%
Revenue 1Y (TTM)19.61%
Revenue growth 3Y27.61%
Revenue growth 5Y24.48%
Sales Q2Q%27.78%
3.2 Future
- Based on estimates for the next years, NBIX will show a very strong growth in Earnings Per Share. The EPS will grow by 32.54% on average per year.
- NBIX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.05% yearly.
EPS Next Y55.94%
EPS Next 2Y47.98%
EPS Next 3Y37.96%
EPS Next 5Y32.54%
Revenue Next Year21.39%
Revenue Next 2Y20.02%
Revenue Next 3Y16.15%
Revenue Next 5Y12.05%
3.3 Evolution
- The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 31.67, which means the current valuation is very expensive for NBIX.
- Based on the Price/Earnings ratio, NBIX is valued cheaper than 92.95% of the companies in the same industry.
- NBIX is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.38, which is the current average of the S&P500 Index.
- The Price/Forward Earnings ratio is 18.38, which indicates a rather expensive current valuation of NBIX.
- Based on the Price/Forward Earnings ratio, NBIX is valued cheaply inside the industry as 94.29% of the companies are valued more expensively.
- When comparing the Price/Forward Earnings ratio of NBIX to the average of the S&P500 Index (24.29), we can say NBIX is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 31.67 | ||
| Fwd PE | 18.38 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, NBIX is valued cheaply inside the industry as 94.29% of the companies are valued more expensively.
- Based on the Price/Free Cash Flow ratio, NBIX is valued cheaply inside the industry as 95.05% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 22.26 | ||
| EV/EBITDA | 19.39 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- NBIX has an outstanding profitability rating, which may justify a higher PE ratio.
- NBIX's earnings are expected to grow with 37.96% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.57
PEG (5Y)0.54
EPS Next 2Y47.98%
EPS Next 3Y37.96%
5. Dividend
5.1 Amount
- NBIX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
132.39
-0.96 (-0.72%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-28 2025-10-28/amc
Earnings (Next)02-04 2026-02-04/amc
Inst Owners99.58%
Inst Owner Change0.08%
Ins Owners1.01%
Ins Owner Change0.24%
Market Cap13.20B
Revenue(TTM)2.68B
Net Income(TTM)428.00M
Analysts84.57
Price Target182.16 (37.59%)
Short Float %4.16%
Short Ratio3.74
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.55%
Min EPS beat(2)7%
Max EPS beat(2)26.1%
EPS beat(4)2
Avg EPS beat(4)-22.42%
Min EPS beat(4)-85.62%
Max EPS beat(4)26.1%
EPS beat(8)3
Avg EPS beat(8)-23.05%
EPS beat(12)4
Avg EPS beat(12)-75.32%
EPS beat(16)4
Avg EPS beat(16)-76.53%
Revenue beat(2)2
Avg Revenue beat(2)3.84%
Min Revenue beat(2)3.28%
Max Revenue beat(2)4.39%
Revenue beat(4)2
Avg Revenue beat(4)1.34%
Min Revenue beat(4)-2.16%
Max Revenue beat(4)4.39%
Revenue beat(8)4
Avg Revenue beat(8)1.12%
Revenue beat(12)6
Avg Revenue beat(12)0.97%
Revenue beat(16)9
Avg Revenue beat(16)1.1%
PT rev (1m)2.49%
PT rev (3m)7.23%
EPS NQ rev (1m)0.96%
EPS NQ rev (3m)6.19%
EPS NY rev (1m)-0.17%
EPS NY rev (3m)13.2%
Revenue NQ rev (1m)-0.19%
Revenue NQ rev (3m)2.06%
Revenue NY rev (1m)-0.14%
Revenue NY rev (3m)2.32%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 31.67 | ||
| Fwd PE | 18.38 | ||
| P/S | 4.92 | ||
| P/FCF | 22.26 | ||
| P/OCF | 20.73 | ||
| P/B | 4.39 | ||
| P/tB | 4.45 | ||
| EV/EBITDA | 19.39 |
EPS(TTM)4.18
EY3.16%
EPS(NY)7.2
Fwd EY5.44%
FCF(TTM)5.95
FCFY4.49%
OCF(TTM)6.39
OCFY4.82%
SpS26.91
BVpS30.12
TBVpS29.77
PEG (NY)0.57
PEG (5Y)0.54
Graham Number53.23
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 10.03% | ||
| ROE | 14.25% | ||
| ROCE | 15.26% | ||
| ROIC | 11.1% | ||
| ROICexc | 16.02% | ||
| ROICexgc | 16.25% | ||
| OM | 20.64% | ||
| PM (TTM) | 15.95% | ||
| GM | 98.37% | ||
| FCFM | 22.11% |
ROA(3y)7.79%
ROA(5y)10.24%
ROE(3y)11.14%
ROE(5y)15.22%
ROIC(3y)11.4%
ROIC(5y)11.57%
ROICexc(3y)30.35%
ROICexc(5y)27.29%
ROICexgc(3y)31.58%
ROICexgc(5y)28.03%
ROCE(3y)15.68%
ROCE(5y)15.92%
ROICexgc growth 3Y35.59%
ROICexgc growth 5Y-0.37%
ROICexc growth 3Y34.3%
ROICexc growth 5Y-0.94%
OM growth 3Y10.53%
OM growth 5Y-2.95%
PM growth 3Y22.39%
PM growth 5Y25.28%
GM growth 3Y-0.06%
GM growth 5Y-0.1%
F-Score5
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 147.14% | ||
| Cap/Sales | 1.63% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 109.17% | ||
| Profit Quality | 138.57% | ||
| Current Ratio | 3.38 | ||
| Quick Ratio | 3.27 | ||
| Altman-Z | 7.86 |
F-Score5
WACC8.83%
ROIC/WACC1.26
Cap/Depr(3y)126.53%
Cap/Depr(5y)144.2%
Cap/Sales(3y)1.41%
Cap/Sales(5y)1.47%
Profit Quality(3y)172.36%
Profit Quality(5y)166.13%
High Growth Momentum
Growth
EPS 1Y (TTM)12.06%
EPS 3Y35.58%
EPS 5Y58.39%
EPS Q2Q%64.52%
EPS Next Y55.94%
EPS Next 2Y47.98%
EPS Next 3Y37.96%
EPS Next 5Y32.54%
Revenue 1Y (TTM)19.61%
Revenue growth 3Y27.61%
Revenue growth 5Y24.48%
Sales Q2Q%27.78%
Revenue Next Year21.39%
Revenue Next 2Y20.02%
Revenue Next 3Y16.15%
Revenue Next 5Y12.05%
EBIT growth 1Y-5.9%
EBIT growth 3Y41.04%
EBIT growth 5Y20.8%
EBIT Next Year4.42%
EBIT Next 3Y19.54%
EBIT Next 5Y18.39%
FCF growth 1Y54.17%
FCF growth 3Y33.71%
FCF growth 5Y32.31%
OCF growth 1Y55.54%
OCF growth 3Y32.41%
OCF growth 5Y31.38%
NEUROCRINE BIOSCIENCES INC / NBIX FAQ
What is the fundamental rating for NBIX stock?
ChartMill assigns a fundamental rating of 7 / 10 to NBIX.
What is the valuation status for NBIX stock?
ChartMill assigns a valuation rating of 8 / 10 to NEUROCRINE BIOSCIENCES INC (NBIX). This can be considered as Undervalued.
What is the profitability of NBIX stock?
NEUROCRINE BIOSCIENCES INC (NBIX) has a profitability rating of 8 / 10.
Can you provide the PE and PB ratios for NBIX stock?
The Price/Earnings (PE) ratio for NEUROCRINE BIOSCIENCES INC (NBIX) is 31.67 and the Price/Book (PB) ratio is 4.39.